At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GH Guardant Health Inc.
Pre-Mkt 08-13 06:51:18 EDT
165.11
+0.02
+0.01%
盘前167.00
+1.89+1.14%
06:14 EDT
High168.37Low162.65Vol1.22M
Open165.89D1 Closing165.09Amplitude3.46%
Mkt Cap22.16BTradable Cap21.43BTotal Shares134.20M
T/O201.98MT/O Rate0.94%Tradable Shares129.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares
Reuters  ·  08-12 06:23
Guardant Health Chief Commercial Officer Chris Freeman Disposes of $ 10.75 Million in Common Shares
Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan
Reuters  ·  08-11 04:13
Guardant Health Grants 46,044 RSUs to 149 New Employees Under Inducement Plan
Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?
Simply Wall St.  ·  08-10
Is GH Research’s Rising Loss Per Share Reframing the GHRS Cash Burn Narrative?
Guardant Health (GH) Following Earnings And Higher Guidance Has Valuation Back In Focus
Simply Wall St.  ·  08-08
Guardant Health (GH) Following Earnings And Higher Guidance Has Valuation Back In Focus
RBC Capital Remains a Buy on GH Research (GHRS)
TIPRANKS  ·  08-08
RBC Capital Remains a Buy on GH Research (GHRS)
Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)
TIPRANKS  ·  08-08
Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)
Movement Alert｜Guardant Health Inc. Rises 5.39% in Regular Trading, Q2 Revenue Beat and Full-Year Guidance Raise Extend Post-Earnings Momentum
Market Focus  ·  08-07
Movement Alert｜Guardant Health Inc. Rises 5.39% in Regular Trading, Q2 Revenue Beat and Full-Year Guidance Raise Extend Post-Earnings Momentum
GH Research is Maintained at Buy by Needham
Dow Jones  ·  08-07
GH Research is Maintained at Buy by Needham
GH Research price target raised to $39 from $32 at Needham
TIPRANKS  ·  08-07
GH Research price target raised to $39 from $32 at Needham
GH Research reports Q2 EPS (23c), consensus (30c)
TIPRANKS  ·  08-06
GH Research reports Q2 EPS (23c), consensus (30c)
GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
Benzinga Earnings  ·  08-06
GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate
Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million
Reuters  ·  08-06
Guardant Health Director Ian T. Clark Disposes of Common Shares Worth $2.25 Million
Guardant Health is Maintained at Overweight by Morgan Stanley
Dow Jones  ·  08-04
Guardant Health is Maintained at Overweight by Morgan Stanley
Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open
Simply Wall St.  ·  08-04
Guardant Health (GH) Filed A Shelf Registration To Keep Future Funding Options Open
Analysts Conflicted on These Healthcare Names: Guardant Health (GH) and Cardinal Health (CAH)
TIPRANKS  ·  08-03
Analysts Conflicted on These Healthcare Names: Guardant Health (GH) and Cardinal Health (CAH)
Guardant Health Shares Climb Following Outlook Raise
Dow Jones  ·  07-31
Guardant Health Shares Climb Following Outlook Raise
Movement Alert｜Guardant Health Inc. Rises 10.72% in Regular Trading, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised
Market Focus  ·  07-31
Movement Alert｜Guardant Health Inc. Rises 10.72% in Regular Trading, Q2 Revenue Significantly Beats Expectations with Full-Year Guidance Raised
RBC Raises Price Target on Guardant Health to $200 From $185, Keeps Outperform Rating
MT Newswires Live  ·  07-31
RBC Raises Price Target on Guardant Health to $200 From $185, Keeps Outperform Rating
Guardant Health is Maintained at Buy by BTIG
Dow Jones  ·  07-31
Guardant Health is Maintained at Buy by BTIG
Guardant Health Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  07-31
Guardant Health Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
No data available

Introduction

Company Name.
Guardant Health Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Issue price:
--